Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
VERACYTE, INC. director Robert S. Epstein reported an open-market sale of 10,000 shares of common stock on May 20, 2026 at a weighted average price of $44.01 per share, with individual sale prices ranging from $44.00 to $44.10.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025. Following these sales, Epstein directly owns 52,446 shares of Veracyte common stock.
Veracyte, Inc. ownership disclosure: Artisan Partners entities report beneficial ownership of 5,496,370 shares of common stock, representing 6.9% of the class based on 79,458,427 shares outstanding as of 02/20/2026. The filing attributes 4,889,589 shares to shared voting power and 5,496,370 shares to shared dispositive power. The shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership and are reported through a joint filing executed 05/13/2026.
State Street Corporation reported beneficial ownership of 5,043,590 shares of Veracyte Inc. common stock, representing 6.3% of the class as of 03/31/2026. The filing lists shared voting power of 4,800,493 shares and shared dispositive power of 5,043,590 shares. The filing identifies several State Street advisory subsidiaries as holders of the position.
VERACYTE, INC. senior vice president and general counsel Annie McGuire reported selling a total of 10,204 shares of common stock in open-market transactions on May 6, 2026. The shares were sold in two blocks at $40.00 and $38.05 per share.
After these sales, she directly owns 143,708 shares of Veracyte common stock. According to a footnote, the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2025, indicating they were scheduled in advance.
Ann McGuire reported a proposed/actual sale of common stock under a 10b5-1 plan. The filing shows a 10b5-1 sale of 6,658 shares on 03/04/2026 that generated $236,725.09. The notice references Performance Stock Units dated 02/28/2026 and lists Morgan Stanley Smith Barney LLC as the broker.
Veracyte Inc. amendment to Schedule 13G/A reports that FMR LLC (and Abigail P. Johnson through related entities) beneficially owns 7,703,848.74 shares of common stock, representing 9.7% of the class. The filing lists sole dispositive power of 7,703,848.74 shares and discloses a related Exhibit 99 13d-1(k)(1) agreement.
Veracyte reported a strong first quarter of 2026, returning solid growth and profitability. Total revenue rose to $139.1 million from $114.5 million a year earlier, driven mainly by a 26% increase in testing revenue to $135.1 million as diagnostic test volume grew 19% to 45,248.
Net income increased to $28.7 million from $7.0 million, with basic EPS rising to $0.36 from $0.09, helped by higher gross profit and lower general and administrative expense. Operating cash flow improved to $35.2 million, and cash, cash equivalents and short-term investments totaled $439.1 million, supporting ongoing investment in R&D and new cancer diagnostic offerings.
Veracyte reported strong first-quarter 2026 results with higher growth and profitability. Total revenue rose 21% to $139.1 million, led by testing revenue of $135.1 million, up 26%, driven by Decipher revenue of $86.5 million and Afirma revenue of $46.4 million.
Profitability improved significantly. GAAP net income was $28.7 million, or 20.6% of revenue, compared with $7.0 million a year earlier, and adjusted EBITDA reached $42.8 million, or 30.8% of revenue. Cash from operations was $35.2 million, and Veracyte ended March 31, 2026 with $439.1 million in cash, cash equivalents and short-term investments.
Management also raised its 2026 outlook. The company now guides total revenue to $582 million–$592 million and testing revenue to $570 million–$580 million, and expects adjusted EBITDA margin to exceed 26%, reflecting confidence in growth from its cancer diagnostic tests and upcoming product launches.
Vanguard Capital Management reports beneficial ownership of 4,132,224 shares of Veracyte Inc, representing 5.20% of the class as of 03/31/2026. The filing shows Vanguard has sole power to dispose of 4,132,224 shares and sole voting power over 599,992 shares. The disclosure attributes ownership to Vanguard Capital Management and affiliated Vanguard entities; signature dated 04/30/2026.